What are some key supply considerations that sponsors need to keep in mind when planning a DCT? What should they look out for when choosing a supply partner?
He talks to us about key developments in the inhalation industry and how the formation of a leading global CDMO can provide support in navigating these changes.
Worth $14 million, entails providing project management and administrative oversight as the IRB of record for Biorepository Protocol and NIAID studies.
Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.